Therapeutics for Duchenne muscular dystrophy: current approaches and future directions
- PMID: 14673527
- DOI: 10.1007/s00109-003-0484-1
Therapeutics for Duchenne muscular dystrophy: current approaches and future directions
Abstract
Duchenne muscular dystrophy (DMD) is the most common X-linked neuromuscular disorder. The devastating nature of DMD has led to an intense effort toward finding a cure for this disease, dating back to the time when Duchenne first initiated clinical trials using faradic stimulation for DMD patients. Unfortunately despite the passage of some 150 years the disease remains incurable, and its medical management is largely supportive. However, the discovery of the DMD gene about 20 years ago has allowed a change in the focus of therapeutic strategy dramatically toward delivery of the missing gene/protein. Indeed, some degree of success has been achieved in preclinical animal studies using such strategies, and gene therapy trials are currently underway in humans. Pharmacological approaches for DMD are also being developed since they can circumvent some of the technical problems associated with gene and cell based therapy. This review explores developments in therapeutic approaches for DMD.
Similar articles
-
Pharmacological strategies for muscular dystrophy.Nat Rev Drug Discov. 2003 May;2(5):379-90. doi: 10.1038/nrd1085. Nat Rev Drug Discov. 2003. PMID: 12750741 Review.
-
Harnessing the potential of dystrophin-related proteins for ameliorating Duchenne's muscular dystrophy.Acta Physiol Scand. 2001 Mar;171(3):349-58. doi: 10.1046/j.1365-201x.2001.00838.x. Acta Physiol Scand. 2001. PMID: 11412148 Review.
-
Multiple regulatory events controlling the expression and localization of utrophin in skeletal muscle fibers: insights into a therapeutic strategy for Duchenne muscular dystrophy.J Physiol Paris. 2002 Jan-Mar;96(1-2):31-42. doi: 10.1016/s0928-4257(01)00078-x. J Physiol Paris. 2002. PMID: 11755781 Review.
-
Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?Trends Mol Med. 2006 Mar;12(3):122-9. doi: 10.1016/j.molmed.2006.01.002. Epub 2006 Jan 27. Trends Mol Med. 2006. PMID: 16443393 Review.
-
An attempt of gene therapy in Duchenne muscular dystrophy: overexpression of utrophin in transgenic mdx mice.Acta Neurol Belg. 2000 Sep;100(3):146-50. Acta Neurol Belg. 2000. PMID: 11098286 Review.
Cited by
-
Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-beta and CTGF/CCN2.J Cell Commun Signal. 2007 Dec;1(3-4):205-17. doi: 10.1007/s12079-008-0018-2. Epub 2008 Apr 15. J Cell Commun Signal. 2007. PMID: 18600480 Free PMC article.
-
Inhibitory control over Ca(2+) sparks via mechanosensitive channels is disrupted in dystrophin deficient muscle but restored by mini-dystrophin expression.PLoS One. 2008;3(11):e3644. doi: 10.1371/journal.pone.0003644. Epub 2008 Nov 4. PLoS One. 2008. PMID: 18982068 Free PMC article.
-
An image processing approach to analyze morphological features of microscopic images of muscle fibers.Comput Med Imaging Graph. 2014 Dec;38(8):803-14. doi: 10.1016/j.compmedimag.2014.07.003. Epub 2014 Jul 31. Comput Med Imaging Graph. 2014. PMID: 25124286 Free PMC article.
-
Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle.Res Sq [Preprint]. 2023 Jun 13:rs.3.rs-3038923. doi: 10.21203/rs.3.rs-3038923/v1. Res Sq. 2023. Update in: Skelet Muscle. 2023 Sep 13;13(1):16. doi: 10.1186/s13395-023-00325-z. PMID: 37398370 Free PMC article. Updated. Preprint.
-
Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.Mol Ther. 2010 Jan;18(1):198-205. doi: 10.1038/mt.2009.248. Epub 2009 Oct 20. Mol Ther. 2010. PMID: 19844193 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
